FDA Extends Review of Belite Bio’s Tinlarebant for Stargardt Disease to May 2027

The FDA has extended its review of Belite Bio’s tinlarebant for Stargardt disease by three months. New PDUFA date is May 12, 2027.

FDA Extends Review of Belite Bio’s Tinlarebant for Stargardt Disease to May 2027
Credit: Belite Bio
Already have an account? Sign in.